1. Name and Address of Reporting Person
   JOHNSON DAVID LEE
   C/O GLOBAL BLOOD THERAPEUTICS, INC.
   181 OYSTER POINT BLVD.
   SOUTH SAN FRANCISCO CA 94080

2. Issuer Name and Ticker or Trading Symbol
   Global Blood Therapeutics, Inc. [GBT]

3. Date of Earliest Transaction (Month/Day/Year)
   04/01/2021

4. If Amendment, Date of Original Filed (Month/Day/Year)
   04/02/2021

5. Relationship of Reporting Person(s) to Issuer
   10% Owner
   Chief Commercial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)
   X Form filed by One Reporting Person
   Form filed by More than One Reporting Person

---

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Date</th>
<th>Security</th>
<th>Code</th>
<th>V</th>
<th>Amount</th>
<th>Price</th>
<th>Transaction(s) Reported</th>
<th>Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/01/2021</td>
<td>Common Stock</td>
<td>M</td>
<td>4,375</td>
<td>A</td>
<td>(I)</td>
<td>31,782</td>
<td>D</td>
</tr>
<tr>
<td>04/01/2021</td>
<td>Common Stock</td>
<td>F</td>
<td>1,513</td>
<td>D</td>
<td>$42.62</td>
<td>30,269</td>
<td>D</td>
</tr>
</tbody>
</table>

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Date</th>
<th>Security</th>
<th>Code</th>
<th>V</th>
<th>(A)</th>
<th>(D)</th>
<th>Date Exercisable</th>
<th>Expiration Date</th>
<th>Title</th>
<th>Amount or Number of Shares</th>
<th>Price of Derivative Security (Instr. 5)</th>
<th>Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/01/2021</td>
<td>Restricted Stock Units</td>
<td>(I)</td>
<td>4,375</td>
<td>(I) (3)</td>
<td>Common Stock</td>
<td>4,375</td>
<td>$0.00</td>
<td>8,750</td>
<td>D</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Explanation of Responses:**
1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
2. Represents number of shares of Issuer's Common Stock sold to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,375 shares of Common Stock underlying the Reporting Person's RSUs.
3. The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019. Thereafter, 1/6th of the remaining underlying shares vest on a semi-annual basis (every six months) until fully vested on April 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

**Remarks:**
/\ Tricia Suvari, Attorney-in-Fact 04/02/2021
** Signature of Reporting Person Date**

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b) (v).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.